Condition: Acute Myeloid Leukemia, in Relapse · Sponsor: Ciceri Fabio
This is a retrospective and prospective non-interventional multicenter observational study. Neither diagnostic approaches nor experimental drugs/procedure will be applied and the samples will take place at the same time as the samples will be taken during routinary clinical practice. The aim of this study is to analyze the immunobiology of Acute Myeloid Leukemia (AML) relapses after allogeneic HSCT for the generation of guidelines and personalized therapeutic pathways.
This description comes directly from the study's public registry record.
Fabio Ciceri, MD · +39 02-2643-3093 · ciceri.clinicaltrials@hsr.it
Stefania Trinca · +39 02-2643-4289 · regolatorio.scp@hsr.it
Always discuss trial participation with your own doctor first.
| IRCCS Ospedale San Raffaele | Milan, Milano, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05124288